Form 4: ZyVersa Therapeutics Director Robert Finizio Granted Stock Options

ZyVersa Therapeutics Director Robert G. Finizio was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.

Summary

• Robert G. Finizio, a Director of ZyVersa Therapeutics, Inc. (ZVSA), was granted 11,066 stock options.
• The options have an exercise price of $0.59 per share.
• The grant date for these options was July 11, 2025.
• The options vest in equal annual installments on the first three anniversaries of the grant date, subject to continued service.
• The expiration date for these options is July 11, 2035.
• Following this transaction, Mr. Finizio directly beneficially owns 11,066 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning management incentives with shareholder interests, indicating a commitment to long-term value creation. It is a standard compensation practice.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• No immediate cash inflow for the director, as these are options, not shares.
• The value of the options is dependent on future stock price appreciation above the exercise price of $0.59.

Risks

• The value of the stock options is subject to the future performance of ZyVersa Therapeutics' common stock.
• Options only become valuable if the stock price exceeds the exercise price of $0.59.

Future Outlook

The options vest in equal annual installments on the first three anniversaries of the grant date, subject to the director's continued service.

Management Comments

• No specific management comments or statements are included in this Form 4 filing.

Industry Context

This Form 4 details an insider transaction, which is a routine disclosure for publicly traded companies. It reflects a common practice of compensating directors with equity to align their interests with shareholders, a standard in the biotechnology and pharmaceutical industries where long-term value creation is key.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across various industries, including biotechnology, aligning director incentives with company performance.
• The vesting schedule over three years is typical for equity grants, promoting long-term commitment.
• The exercise price of $0.59 is the market price at the time of grant, which is standard for incentive stock options.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are disclosed in this document.

Related Party Transactions

• No unusual related party transactions beyond the standard grant of stock options as part of director compensation are disclosed.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with long-term stock performance.

Next Steps

• Continued service of Robert G. Finizio as a director for the options to vest.
• Future exercise of options by Robert G. Finizio, subject to vesting and stock price performance.

Key Dates

Recommendation

Keywords

ZyVersa Therapeutics, ZVSA, Form 4, SEC filing, stock options, insider transaction, director compensation, beneficial ownership